Author: Customer Service

HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) — Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights. “Our team made substantial progress this quarter in advancing our integrated CNS oncology platform including a full repositioning and rebranding of the Company,” said Marc H. Hedrick, M.D., M.B.A., Cerenome President and Chief Executive Officer. “For the remainder of the year, I expect the progress to accelerate across all verticals, highlighted by our buildout of the diagnostic commercial organization.” Q2...

Total Operating Expenses Reduced Approximately 37% Sequentially in the Second Quarter 2026 from the First Quarter 2026, Reflecting Continued Cost Alignment BERA Holdings of Approximately 81.3 Million Units at Quarter-End; BERA-per-Share Increased Approximately 37% from Year-End, While the Fair Value of BERA Holdings Declined During the QuarterBOCA RATON, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) — Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (Nasdaq: GNLN), a publicly traded company with a digital asset treasury strategy focused on the acquisition, management, and strategic deployment of BERA, the native token of the Berachain blockchain network, today reported its financial results for the second quarter ended June 30, 2026 (“second quarter 2026”). Digital Asset Treasury Strategy In October 2025, the Company adopted a...

Cost Reductions Contribute to $3.4M Increase to Net Income from Q1 2026; Company Acquires ConnectAndSell, Expected to Increase FY2026 Revenue to $17M and FY2027 Revenue to $26M Management to Host Second Quarter 2026 Results Conference Call Today, Friday, August 14, 2026 at 4:30 p.m. Eastern Time SEATTLE, Aug. 14, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: PARA) (d/b/a “Parabolic” or the “Company”), a leading AI-powered agentic applications technology company, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 and Subsequent Key Financial & Operational HighlightsCompany expands vision to Agentic Applications for enterprise with Parabolic rebrand Net Loss for Q2 2026 was $5.0 million, compared to Q1 2026 Net Loss of $8.4 million. The Company achieved net dollar...

Motorsport Games Reports Second Quarter 2026 Financial ResultsMotorsport Games reports Q2 2026 results: revenue up 36.6%, a sixth straight profitable quarter, and first half revenue up 74% year over year.MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) today reported financial results for its second quarter ended June 30, 2026. The Company has also posted second quarter 2026 earnings slides highlighting key milestones that occurred during and subsequent to the period, which are accessible on the Company’s investor relations website. “We are delighted to report a sixth consecutive quarter of profitability, with revenues for the first half of the year growing strongly against the same period last year,” commented Stephen Hood, President and Chief Executive...

Second Quarter Revenue Increased 190% Year-Over-Year to $4.7 million, Driven by Contribution from Arps Dairy Acquisition Company Expects to Achieve Adjusted EBITDA Breakeven in Second Half of 2026 Company Revises Full Year 2026 Guidance to Reflect Slower-than-Anticipated Ramp in Production Efficiency at Existing Facility; Remains Focused on Completing Construction of New Defiance, Ohio Facility LOS ANGELES, Aug. 14, 2026 (GLOBE NEWSWIRE) — Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, today reported financial results for the second quarter June 30, 2026. Management Comments Riccardo Delle Coste, the Company’s Chief Executive Officer, stated, “Our education channel continued to rebuild in the second quarter, as former customers returned and...

Operating cash flow turned positive for the quarter as sequential Operating EBITDA improved by $1 million Hauppauge, NY, Aug. 14, 2026 (GLOBE NEWSWIRE) — – Cemtrex, Inc. (Nasdaq: CETX, CETXP) today reported results for the 2026 third fiscal quarter ended June 30, 2026. Key Highlights for Third Fiscal Quarter 2026Revenue increased 9% year-over-year to $18.4 million, up 2% sequentially from the second fiscal quarter. Consolidated operating loss narrowed to $1.2 million from $2.2 million in Q2, the second consecutive quarter of sequential improvement. Operating EBITDA improved to a loss of $0.6 million, from a loss of $1.7 million in Q2 and a loss of $2.5 million in Q1. Operating EBITDA is a non-GAAP measure defined and reconciled below. Security segment operating loss narrowed to $0.3 million, from $1.4 million in Q2 and $3.0 million...

Evaluating Four Separate Non-Binding Offers for the Sale of CMD, Each Contemplating a Purchase Price of Approximately $65 Million — Approximately 3.5x the $18.8 Million Purchase Price Paid in December 2024 Q2 2026 Operating Loss from Continuing Operations Improved 57% Year-over-Year to Approximately $459,000, Compared with $1.1 Million in Q2 2025 Q2 2026 Gross Margin from Continuing Operations Expanded Approximately 600 Basis Points to 45.4%, While Operating Expenses Declined 29% Year-over-Year Company Generated Approximately $712,000 of Positive Operating Cash Flow from Continuing Operations in the First Half of 2026, an Increase of Approximately 18% Year-over-Year NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) — 1847 Holdings LLC (OTC: LBRA) (“1847 Holdings” or the “Company”), a diversified acquisition holding company focused on identifying...

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Expected in 2H 2027 BOTHELL, Wash., Aug. 14, 2026 (GLOBE NEWSWIRE) — LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today reported financial results for the quarter ended June 30, 2026, and provided recent pipeline and business updates. “We enter the second half of 2026 with a clear focus on executing our Phase 3 ELAINE-3 trial and advancing lasofoxifene toward what we believe could be a transformative treatment option for patients with ESR1-mutated metastatic breast cancer,” said Mark Litton, Ph.D., President and Chief Executive...

Key Facts At-a-GlanceWho: Ambow Education Holding Ltd. (NYSE American: AMBO) What: Unaudited financial and operating results for the three-month and six-month periods ended June 30, 2026 When: Reported August 14, 2026; Quarterly Report on Form 10-Q filed with the SEC the same day First Half Revenue: Net revenues increased 2.0% to $5.2 million from $5.1 million in the first half of 2025 Second Quarter Revenue: Net revenues decreased 14.3% to $2.4 million from $2.8 million in the second quarter of 2025 Margin: First half gross profit margin expanded to 55.8% from 54.9% Balance Sheet: Cash resources of $7.2 million as of June 30, 2026, and positive working capital of $5.5 millionCUPERTINO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (“Ambow” or the “Company”) (NYSE American: AMBO), an innovator in AI-powered...